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Patient reporting suggests that the physical and psychological effects of autoimmune hepatitis (AIH) can be substantial. 
However, health-related quality of life (HRQOL) in patients with AIH remains incompletely characterized, and health util-
ity remains to be explored. Treatment for AIH often includes the use of corticosteroids, which are agents that can be associ-
ated with significant adverse effects. Here we explore the impact of AIH and its treatments on patient-reported HRQOL and 
health utility in a large cohort of prevalent cases from the United Kingdom Autoimmune Hepatitis (UK-AIH) national 
study. Data were collected from 990 adult participants with a clinical diagnosis of AIH using validated HRQOL tools in-
cluding the European Quality-of-Life 5-Dimension 5-Level (EQ-5D-5L) and clinical data forms. The EQ-5D-5L dimen-
sion scores were compared with UK population norms and with a disease control cohort with primary biliary cholangitis 
(PBC). Within the AIH cohort, regression analysis was used to explore associations between HRQOL and demographic and 
clinical variables with a particular focus on the impact of AIH therapies including corticosteroid use. HRQOL, measured by 
the EQ-5D-5L utility index, is shown to be significantly impaired in our cohort of AIH patients compared with population 
norms. Within the AIH cohort, corticosteroid use was found to be significantly associated with impaired HRQOL, even 
when controlling for biochemical disease activity status. Conclusion: Our data show evidence of HRQOL impairment in a 
large cohort of AIH patients compared with the general population. Furthermore, corticosteroid use is strongly associated 
with decreased HRQOL, independent of remission status. This highlights the need for better corticosteroid-free therapy 
approaches and it emphasizes the need for future novel therapeutic trials in AIH. (Hepatology 2018; 68:1487-1497).
Autoimmune hepatitis (AIH) is a rare immune-mediated chronic liver disease that, if under-treated, results in progressive liver 
injury leading to cirrhosis, hepatic failure or death. 
AIH remains a diagnostic and therapeutic challenge 
with at least a third of patients presenting with cir-
rhosis, a fifth having relapsing disease, and 30%-50% 
developing cirrhosis despite treatment.(1) AIH there-
fore has the potential to cause significant medical and 
economic burdens on affected patients and health care 
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delivery systems, respectively. Current management of 
AIH largely comprises corticosteroids alone (mainly 
prednisolone) or in combination with azathioprine, 
with 38%-93% of patients achieving remission,(2,3) but 
up to 90% having a disease relapse after withdrawal 
of therapy.(4) Other second-line immunosuppressants 
include mycophenolate mofetil (MMF), cyclosporine, 
and tacrolimus, but these lack evidence based on ran-
domized controlled trials. All these agents, particu-
larly corticosteroids, can be associated with important 
adverse effects such as the metabolic syndrome with its 
sequelae, osteoporosis, weight gain, and disturbance in 
sleep and mood.(5-9)
In addition to its clinical impact as a result of dis-
ease progression to cirrhosis, up to 50% of patients with 
AIH are symptomatic with fatigue, general ill health, 
abdominal pain, and joint pain, despite treatment.(10,11) 
Patient reports suggest that the physical and psycho-
logical effects of AIH on patients can be substantial. 
These remain, however, incompletely characterized,(4) 
and it can be challenging to separate these from adverse 
effects attributable to the treatment used for AIH. 
The nature and extent of the impact of AIH and its 
symptoms and treatments on health-related quality of 
life (HRQOL) has not been widely reported. A sur-
vey among members of the Dutch liver patient asso-
ciation evaluated HRQOL in liver disease of different 
etiologies using the Dutch Short Form Survey-36 
(SF-36), the Liver Disease Symptom Index 2.0 and 
the Multidimensional Fatigue Index-20. The subset 
of patients with AIH (n = 142) had significantly lower 
scores (and thus worse HRQOL) in all SF-36 scales 
(particularly, physical problems or general health scales), 
as well as significantly worse fatigue scores (reported via 
the Multidimensional Fatigue Index-20 questionnaire) 
compared with Dutch healthy controls.(12) A study 
of 24 children with AIH or with Primary Sclerosing 
Cholangitis/AIH overlap using the Pediatric Quality 
of Life (PedsQL) 4.0 questionnaire showed signifi-
cant impairment of HRQOL. This was associated with 
the presence of frequent liver disease-related symp-
toms (particularly, abdominal pain, fatigue, and mood 
symptoms).(13) More recently, a German single-center 
study (n = 103) using patient-reported HRQOL data 
found higher rates of depression and anxiety in AIH 
patients compared with the general population. A 
major associated factor was concern regarding the risk 
and implications of progressive liver disease. There was 
also a correlation found between prednisolone use and 
depression.(14) A Polish single-center study (reported 
in abstract form) found that a population of patients 
(52 with AIH had reduced HRQOL according to the 
SF-36, Modified Fatigue Impact Scale, and Patient 
Health Questionnaire-9) compared with a matched 
healthy-control group.(15) Finally, a Canadian study 
(n = 52) described an association between psychosocial 
distress, nonadherence to treatment, and incomplete 
response to therapy in AIH.(16) Studies on health- 
related quality of life (HRQOL) in AIH have been 
mainly single-center with small numbers, but these 
suggest that there is a significant issue with quality of 
life (QOL) in AIH and that further formal exploration 
of its impact is warranted.(12-16)
QOL is a critically-important issue for patients, 
and one that is increasingly prioritized by regulatory 
bodies when evaluating the benefits of new drugs. A 
deeper understanding of HRQOL is therefore essen-
tial if we are to make progress with therapy in AIH. 
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In this study, we utilized a unique cohort of prevalent 
cases in the United Kingdom-AIH (UK-AIH) study 
cohort to explore the impact of AIH and its treatments 
on patient life quality using the European Quality-of-
Life 5-Dimension 5-Level (EQ-5D-5L) tool to eval-
uate HRQOL.(17) We also used the data to calculate 
health state utilities, values which represent an indi-
vidual's preferred value for specific health states rela-
tive to full health, which are fundamental in assessing 
cost-effectiveness and cost utility of the management 
of disease.(18) As fatigue, cognitive impairment, anxi-
ety and depression are important symptoms that have 
been reported in chronic liver diseases and have signif-
icant impact on QOL,(12,14,19-21) we used three other 
qualitative tools (the Fatigue Impact Scale [FIS],(22) 
the Cognitive Failure Questionnaire [CFQ],(23) and 
the Hospital Anxiety Depression Scale [HADS])(24) 
to explore the impact of specific symptom sets on 
HRQOL and health utilities.
Patients and Methods
STUDY POPULATION
UK-AIH is a cross-sectional cohort study open to 
adult patients (≥16 years) with a current clinical diag-
nosis of AIH (as evaluated by their treating clinician) 
who were recruited from a secondary hospital care set-
ting between March 2014 and January 2017. Patients 
had to be living in the United Kingdom and all patients 
provided written informed consent for use of data. 
The protocol was approved by the National Health 
Service (NHS) Health Research Authority (IRAS ID: 
144806, REC reference: 14/LO/0303) and was con-
ducted in accordance with the International Council 
for Harmonization Good Clinical Practice guidelines 
and the Declaration of Helsinki.
QUALITY OF LIFE AND SYMPTOM 
IMPACT MEASURES
Health-related quality of life and symptom impact 
information was collected using patient-reported 
EQ-5D-5L, FIS, CFQ and HADS tools.
The European Quality-of-life 5-Dimension 5-Level 
(EQ-5D-5L) tool is a simple, generic HRQOL instru-
ment comprising five health dimensions which gener-
ates a health utility index (UI) and a visual analogue scale 
(VAS). The European Quality-of-life 5-Dimension 
(EQ-5D) tool was first introduced as a three-level 
version (EQ-5D-3L) in 1990 with three levels of 
severity (no problems, some problems, and extreme 
problems), and was subsequently revised in 2009 to 
include five levels of severity (EQ-5D-5L) in order to 
improve the instrument's sensitivity and reduce ceiling 
effects compared with EQ-5D-3L.(17,25) The EQ-5D 
tool has been used to evaluate HRQOL in a wide spec-
trum of diseases including liver disease, notably hepati-
tis C,(26) hepatitis B,(27) liver transplantation,(28) and other 
chronic liver diseases. The EQ-5D-5L is widely used 
internationally as a patient-reported outcome measure 
and is the preferred tool of England's health authority, 
the National Institute for Health and Care Excellence 
(NICE), for use in cost-effectiveness analysis.(29) The 
EQ-5D-5L tool comprises the EQ descriptive system 
of five health dimensions (mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression) and 
the EQ-visual analogue scale (EQ-VAS). Each health 
dimension has five levels (scored from 1 to 5): no prob-
lems, slight problems, moderate problems, severe prob-
lems and extreme problems. The respondent indicates 
his/her health state by ticking the box against the most 
appropriate statement in each of the five health dimen-
sions. Utility Index (UI) is then calculated from these 
five health dimensions using the EQ-5D-5L Value 
Set for England.(30) The UI ranges from -0.28 (‘worst 
possible health’) to 1.00 (‘best possible health’). The 
EQ-VAS records the participants' self-rated health 
on a vertical VAS with end-points labelled “the worst 
health you can imagine” (0) at the bottom of the scale 
and “the best health you can imagine” (100) at the top 
of the scale, respectively. A higher UI and VAS denote 
a higher HRQOL. For the purpose of this manuscript, 
the term UI is used to represent HRQOL.
The FIS tool is an assessment tool developed to eval-
uate the impact of fatigue on the activities and quality 
of daily life. It has been validated in chronic fatigue 
syndrome, multiple sclerosis,(22) and primary biliary 
cholangitis (PBC).(31) It consists of 40 items address-
ing the impact of fatigue on aspects of daily life (maxi-
mum score 160), containing three intermixed domains 
addressing physical, cognitive (maximum score 40 
each) and psychosocial (maximum score 80) elements 
of fatigue. The FIS is scored on a 5-point Likert scale 
(0 = no problem to 4 = extreme problem). The higher 
the total score, the higher the impact of fatigue.
The CFQ is a tool that assesses the prevalence of 
cognitive symptoms by measuring the frequency of 
cognitive slips or failures occurring in everyday life. 
These include memory, attention, concentration, 
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forgetfulness, word-finding abilities, and confusion. 
The questionnaire consists of 25 questions encompass-
ing failures in perception, memory and motor func-
tion. The patient rates how often these failures occur 
on a five-point Likert scale of 0-4 (0 = never, 4 = very 
often). The responses are summed to obtain a total 
CFQ score. The higher the score, the greater the cog-
nitive impairment (overall range 0-100).(23)
The HADS tool is a validated 14-item mea-
sure of current anxiety (HADS-A) and depression 
(HADS-D) optimized for use in patients with chronic 
disease.(24) It was developed as a screening instrument 
for use in a hospital outpatient setting and is aimed 
at detecting the presence and severity of depression 
and anxiety in nonpsychiatric settings.(32) Anxiety and 
depression subscales (comprising 7 items) are scored 
separately (ranging 0-21 for each subscale). For each 
subscale, a score of 0-7 indicates no anxiety or depres-
sion, 8-10 borderline “caseness,” and a score of ≥11 is 
clinically significant, indicating “caseness” for depres-
sion or anxiety.(19,24)
CLINICAL DATA COLLECTION, 
GROUP COMPARISON AND GROUP 
SUBTYPES
Demographic and clinical data were collected from 
patient records by study team members using clinical 
data forms. Patients with previous liver transplantations 
were excluded from this analysis. Clinical data was col-
lected on sex,age at inclusion of study, year of diagnosis, 
biochemical results on recruitment date (serum alanine 
transferase [ALT] and Immunoglobulin G [IgG]) 
or within 12 months of recruitment date, number of 
flares in the past 12 months, immunosuppressive treat-
ment, presence of cirrhosis (defined histologically or 
clinically by radiological evidence or transient elastog-
raphy) and diagnosis of osteoporosis (on diagnosis of 
AIH and since diagnosis). Biochemical remission was 
defined as normal ALT and IgG at the time of recruit-
ment (and within the preceding 12 months) with no 
documented flares in the last 12 months. A flare was 
defined as an abnormal ALT above the upper limit 
of normal (ULN) requiring an increase or addition of 
corticosteroid treatment. The upper limit of normal 
(ULN) used for ALT and IgG levels were based on 
each site's pathology laboratory ULN.
Ethnicity and data on other medical conditions 
including PBC, primary sclerosing cholangitis (PSC), 
ulcerative colitis or Crohn’s disease, and rheumatoid 
arthritis (RA) were collected using patient-reported 
“tick-box” questionnaires.
A cohort of PBC patients obtained from the 
UK-PBC cohort (n = 1665) with known age, sex, 
European quality-of-life 5-dimension 5-level utility 
index (EQ-5D-5L UI) and EQ-VAS scores were used 
for comparison.(33)
STATISTICAL ANALYSIS
The cohort was characterized descriptively, with 
categorical variables presented as frequencies and 
percentages and continuous variables presented as 
medians and ranges due to underlying distributional 
assumptions. To compare HRQOL with UK popula-
tion norms, the EQ-5D-5L dimension scores in our 
cohort were converted to EQ-5D-3L index values 
using the crosswalk calculator, as there are currently 
no published population norms available using the 
EQ-5D-5L value set. The crosswalk calculator deter-
mines a UI value for each EQ-5D-5L state by first 
predicting the likelihood of being in each EQ-5D-3L 
state and, secondly, calculating the weighted sum of the 
UI values across the EQ-5D-3L states. This is based 
on an analysis of data from coadministering both 
tools to 3,691 respondents.(34) These values were then 
compared with EQ-5D-3L values of UK population 
norms(35) using the two sample t test after standard-
ization for age and sex and reported as mean (standard 
deviation).
Regression analysis was used to explore the associa-
tion of various demographic and clinical covariates with 
HRQOL in our cohort. The primary outcome measure 
of interest was UI, a continuous measure of HRQOL. 
Due to the highly-skewed nature of this variable, we 
used quantile regression with the median as the chosen 
quantile. Regression models were developed for each 
covariate of interest and models were adjusted for age, 
sex, and biochemical remission status, as appropriate.
Further regression analysis was used to explore the 
relationship between various other HRQOL outcome 
measures and corticosteroid use. These outcome mea-
sures included the five individual health dimensions of 
the EQ-5D-5L (analyzed using ordinal regression), 
continuous measures FIS and CFQ (analyzed using 
quantile regression), and the three-level classification 
of HADS-A and HADS-D (analyzed using ordinal 
regression). Data were analyzed using STATA version 
14.1, R version 3.3.0.
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Results
DEMOGRAPHIC, CLINICAL AND 
HRQOL CHARACTERISTICS
Data from 990 patients were analyzed from 39 hos-
pitals (32 nontransplant centers and 7 transplant cen-
ters). Table 1 shows the clinical characteristics of the 
study population and self-reported comorbidities. For 
further details on therapy regimens, see Supporting 
Table S1. Table 2 summarizes the HRQOL and symp-
tom severity characteristics.
Of the study participants, 795 (80%) were female 
and 92% of Caucasian ethnicity. The median age at 
inclusion in the study was 58 years (17-95) and median 
duration of disease was 7 years (0-57). A total of 79% 
of those with available data had positive antinuclear 
antibody (ANA), or smooth muscle antibody (SMA), 
or soluble liver antigen (SLA) antibodies, and 1% had 
anti-Liver-Kidney Microsomal (LKM) positivity. 
Altogether, 558 (56%) were in biochemical remission, 
545 (55%) of patients were on corticosteroids, and 330 
(33%) had cirrhosis. There were 25 (3%) patients on 
triple immunosuppression (i.e., taking two immuno-
suppressants and corticosteroids).
HRQOL AND UTILITY 
ABNORMALITY IN AIH
The median EQ-5D-5L UI value was 0.89 (-0.19-
1.00) and the median EQ-VAS was 80 (10-100). The 
distribution of EQ-5D-5L responses can be seen in 
Fig. 1, split by health domain. Of the five domains, the 
pain/discomfort domain had the highest proportion of 
patients reporting problems (57%), while the self-care 
domain had the lowest (11%). Following conversion to 
EQ-5D-3L index values using the crosswalk calcula-
tor,(34) the mean UI (0.77, SD = 0.23, standardized for 
sex and age) was significantly lower in our cohort (t = 
11.4, P <0.001) compared with UK population norms 
(0.86, SD = 0.23).
When comparing our cohort of AIH patients to a 
large cohort of PBC patients (n = 1665, median age: 
67 years [29-95], 91% female), we found no statistically 
significant difference in UI between the two groups, 
after controlling for age and sex (β = 0. 008, P = 0.41). 
On graphical comparison of the EQ-5D-5L responses 
according to health domains between AIH and PBC, 
the proportion of patients experiencing problems in 
each of the subdomains appear similar between the two 
groups. (See Supporting Fig. S1.)
TABLE 1. Clinical Characteristics of the Study Population
Biochemical Tests
ALT (IU/L) (n = 965) 25.0 (4.0-1315.0)
ALT:ULN ratio 0.6 (0.1-35.0)
IgG (g/L) (n = 742) 12.5 (2.1-51.1)
IgG:ULN ratio 0.8 (0.2-3.2)
Biochemical Remission
Normal ALT only (according to each site's 
ULN [n = 965])
758 (78.5)
Normal ALT and IgG (n = 736) 449 (61.0)
Normal ALT and IgG with no documented 
flares last 12 months (used in regression 
analysis [n = 990])
558 (56.4)
Therapy and Dose per day (n = 990)
Prednisolone 499 (50.4)
Dose, mg 5 (0.2-60)
Budesonide 47 (4.7)
Dose, mg 3 (0.4-9)
Azathioprine 581 (58.7)
Dose, mg 100 (25-250)
Dose/weight, mg/kg 1.1 (0.2-2.8)
6-Mercaptopurine 48 (4.8)
Dose, mg 50 (12-150)
Dose/weight, mg/kg 0.7 (0.1-2.0)
Mycophenolate (MMF/MA) 166 (16.8%)
Dose, mg 1,000 (200-3,000)
Tacrolimus 41 (4.1)
Dose, mg 2 (0.5-9)
Cyclosporine 6 (0.6)
Dose, mg 125 (50-300)
Self-reported comorbidities (n = 956)
Primary biliary cholangitis 64 (6.7)
Primary sclerosing cholangitis 22 (2.3)
Ulcerative colitis/Crohn's 48 (5.0)
Rheumatoid arthritis 60 (6.3)
Osteoporosis 147 (15.4)
Note: Data are presented as n (%) or median (range), unless noted 
otherwise.
TABLE 2. HRQOL and Symptom Impact Characteristics
HRQOL Measures
EQ-5D-5L UI (n = 986) 0.89 (-0.19 - 1.00)
EQ-VAS (n = 985) 80 (10-100)
FIS (n = 950) 27 (0-160)
CFQ (n = 950) 32 (0-100)
HADS-A score (n = 966) 5 (0-21)
HADS-D score (n = 965) 3 (0-18)
HADS-A score classifications (n = 966)
No anxiety (0-7) 637 (65.9)
Borderline (8-10) 181 (18.7)
Clinically significant (≥11) 148 (15.3)
HADS-D score classifications (n = 965)
No depression (0-7) 816 (84.6)
Borderline (8-10) 96 (9.9)
Clinically significant (≥11) 53 (5.5)
Note: Data are presented as n (%) or median (range), unless noted 
otherwise.
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ASSOCIATION BETWEEN 
DEMOGRAPHIC AND CLINICAL 
FACTORS AND HRQOL/UTILITY
The results of univariable quantile regression are 
presented in Table 3. In the unadjusted regression anal-
ysis, we observed that increasing age and body mass 
index (BMI) are both associated with lower UI (β = 
-0.001, P <0.001 and β = -0.006, P <0.001 respectively) 
and female sex is associated with higher UI (β = 0.034, 
P = 0.027). We did not find any evidence that the place 
of care (transplant centers versus nontransplant cen-
ters) is associated with UI (β = 0.000, P = 1.000).
Patients who are in biochemical remission appear to 
have significantly higher UI (β = 0.024, P = 0.020) than 
those not in biochemical remission, after controlling 
for age and sex. In all subsequent models discussed, we 
controlled for age, sex and remission status. We did not 
observe any association between UI and having cir-
rhosis or duration of disease. We also explored lower 
cut-offs for normality for ALT, adopting the hepati-
tis B virus cut-offs (<30 IU/L for males and <19 for 
females)(36) and did not find any association between 
UI and these lower cut-off levels.
When considering the association between 
patient-reported comorbidities and HRQOL, we 
found that patients who reported having either PBC 
(β = -0.046, P = 0.033), PSC (β = -0.090, P = 0.005) or 
RA (β = -0.053, P = 0.008) have impaired UI compared 
with AIH patients not reporting these comorbidities. 
We did not find any evidence of an association between 
self-reported osteoporosis or inflammatory bowel dis-
ease in our cohort.
ASSOCIATION BETWEEN AIH 
THERAPIES AND HRQOL/UTILITY
We found that corticosteroid use was significantly 
associated with lower UI (β = -0.030, P = 0.006) and this 
was irrespective of being on low-dose corticosteroids 
(<10 mg prednisolone or <6 mg budesonide per day) or 
high-dose corticosteroids (≥prednisolone 10 mg or ≥6 
mg budesonide per day). (See Table 3) Furthermore, 
within the group on corticosteroids, we did not find 
any evidence that dose was associated with mate-
rial difference in HRQOL impairment, with impact 
still being seen in patients on low dose corticosteroid 
(Table 3). We did not find any evidence that the reduc-
tion in UI seen in corticosteroid users was different for 
patients in biochemical remission compared with those 
not in biochemical remission (this was explored via the 
addition of an interaction term to the model result-
ing in a nonsignificant coefficient, (β = -0.013, P = 
0.486). Additionally, we found that calcineurin inhib-
itor (CNI) use was also significantly associated with a 
lower UI (β = -0.077, P = 0.002). Even after controlling 
for corticosteroid use, CNI use remained significantly 
associated with lower UI (β = -0.067, P = 0.008). We 
did not find any evidence of association between aza-
thioprine/6-mercaptopurine (6MP) or Mycophenolate 
mofetil (MMF)/Mycophenolic acid (MA) use and 
impaired QOL. Furthermore, we found no evidence 
of a difference between corticosteroid monotherapy 
and combination therapy with azathioprine (explored 
via the addition of an interaction term to the model 
resulting in a nonsignificant coefficient, β = -0.024, 
P = 0.177).
FIG. 1. Distribution of EQ-5D-5L 
responses levels, split by health domain 
(whole cohort).
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Further investigation of individual health states 
within the EQ-5D-5L (Table 4) showed that cortico-
steroid use was associated with increased problems in 
the mobility (β = 0.307, P = 0.026) and usual activities 
(β = 0.426, P = 0.002) domains. There was evidence of 
a borderline association between corticosteroid use and 
increased problems in the anxiety/depression domain 
(β = 0.267, P = 0.043). We did not find evidence of 
an association between corticosteroid use and the self-
care or pain/discomfort domains.
Additional HRQOL measures (FIS, CFQ, 
HADS-A and HADS-D) are considered in Table 4, 
where their associations with corticosteroid use are 
explored. We observe impaired HRQOL for cortico-
steroid users with respect to all HRQOL measures, 
with the association between corticosteroid use and FIS 
(β = 9.50, P <0.001) reaching statistical significance.
Discussion
This large and comprehensive study of quality of life 
in AIH explores health utility in this disease. Health util-
ity is a critical parameter that plays an integral role in the 
assessment of the value of current and emerging therapies 
in disease. The multi-center nature of the patient popu-
lation (a combination of liver transplant centers, tertiary 
hospitals and district general hospitals) ensures a com-
prehensive spectrum of patients and provides important 
real-world data. Our key findings are that quality of life 
and health utility impairment in AIH are significant 
(and similar in degree to those seen in PBC)(19) and that 
the nature of the treatment used in AIH, in particular 
the use of corticosteroids, is potentially a key driver for 
impaired quality of life and health utility. Health utility 
in AIH should be included in the assessment of treat-
ment approaches in AIH and improvement of health 
states should be a goal for future therapy approaches, 
alongside the conventional target of prevention of dis-
ease progression.
Achieving a state of biochemical remission, in which 
surrogate serum markers of disease activity are normal-
ized, was associated with significantly better health 
utility outcomes after controlling for age and sex. In 
the German study by Schramm and colleagues, which 
found reduced mental wellbeing in their patients with 
AIH, the majority (77%) were in biochemical remis-
sion.(14) This compares with the 56% remission rate in 
our “real world” nationwide patient cohort. Our rela-
tively lower proportion of patients in remission may 
TABLE 3. Regression Analysis Investigating Factors Associated With EQ-5D-5L Utility Index Value.
Outcome Variable Predictor Coefficient (β) 95% CI P Value
EQ-5D-5L UI value Demographic
Age at inclusion -0.001 (-0.002, -0.001) <0.001
BMI -0.006 (-0.008, -0.005) <0.001
Sex, female 0.034 (0.004, 0.064) 0.027
Transplant center 0.000 (-0.021, 0.021) 1.000
Clinical covariatesa
In biochemical remissionb 0.024 (0.004, 0.043) 0.020
Has cirrhosis 0.013 (-0.009, 0.035) 0.245
Duration of disease 0.001 (-0.000, 0.002) 0.202
“Normal ALT” using lower cut-offs ALT (ALT <30 for males, ALT <19 for females) 0.006 (-0.016, 0.029) 0.587
Treatmenta
Prednisolone/budesonide -0.030 (-0.051, -0.009) 0.006
Low dose corticosteroid (defined as either <10 mg prednisolone/day or <6 mg 
budesonide/day)
-0.027 (-0.050, -0.004) 0.021
High dose corticosteroid (≥10 mg prednisolone/day or ≥6 mg budesonide/day) -0.035 (-0.067, -0.004) 0.028
Corticosteroid dose (log-transformed)
(corticosteroid users only, n = 545)
-0.006 (-0.028, 0.016) 0.582
Azathioprine / 6-mercaptopurine 0.009 (-0.011, 0.030) 0.356
MMF/MA -0.007 (-0.035, 0.020) 0.594
Tacrolimus/cyclosporine (CNIs) -0.077 (-0.124, -0.030) 0.002
Patient reported comorbiditiesa
PBC -0.046 (-0.088, -0.004) 0.033
PSC -0.090 (-0.154, -0.027) 0.005
Rheumatoid arthritis -0.053 (-0.092, -0.014) 0.008
Osteoporosis -0.023 (-0.052, 0.007) 0.132
Ulcerative colitis/Crohn's -0.031 (-0.076, 0.014) 0.177
aControlling for age, sex & remission status.
bControlling for age and sex.
WONG, FISHER, ET AL. HEPATOLOGY, October 2018
1494
be due to the stricter definition for biochemical remis-
sion applied in our study, which takes into account the 
reported trend of the biochemical parameters in the 
previous 12 months. Incomplete biochemical remission 
(failure of transaminases and IgG levels to normalize) 
is predictive of relapse after treatment withdrawal, 
histological activity, progression to cirrhosis, and poor 
outcome.(4) Ongoing inflammation in a patient not in 
remission would be an obvious potential explanation 
for reduced utility. Patients who have not achieved 
complete biochemical remission are more likely to be 
on dual or triple immunosuppression (potentially at 
higher doses) and have had more courses of corticoste-
roids, and they are at increased risk of complications of 
progressive disease. All these factors could also impact 
quality of life and utility. In our analysis, cirrhosis did 
not emerge as a cofactor associated with poorer utility, 
even after controlling for age, sex and remission status. 
Schramm et al also found that the presence of cirrho-
sis in AIH patients was not significantly associated 
with depressive symptoms and the physical component 
score of the 12-Item Short-Form Health Survey (SF-
12) in the AIH patients did not differ between those 
with and without cirrhosis.(14)
The most striking finding in our study was that cor-
ticosteroids were associated with significantly lower 
levels of utility, even after controlling for age, sex and, 
crucially, biochemical remission status. This effect was 
seen for both high-dose and low-dose corticosteroid 
therapy. On further analysis of the five EQ-5D-5L 
health domains, corticosteroid use was associated with 
increased problems with mobility and usual activities. 
One of the well-known adverse effects of cortico-
steroids is weight gain. Almost a third (31%) of our 
patients on corticosteroids were obese with BMI ≥30, 
which may contribute to problems in mobility and 
usual activities. Corticosteroids were the first therapy 
shown to improve the outcome of patients with AIH 
by significantly reducing mortality compared with 
 placebo in the early controlled trials. However, these 
trials reported a high proportion of corticosteroid- 
related adverse effects including Cushingoid features in 
20%-50% of patients, diabetes in 15%-20%, hyper-
tension, cataracts, psychosis, and osteoporotic verte-
bral collapses in 5%-10%.(1,5-8) Subsequent studies 
reported a 30%-53% prevalence of corticosteroid- 
related side-effects.(9,37,38) Despite the adverse effects 
associated with corticosteroids, a significant proportion 
(38%-85%) of patients remain on corticosteroids in the 
long term.(39,40) The impact of corticosteroids on QOL 
has been studied in other diseases dependent on long-
term corticosteroids, such as systemic lupus erythema-
tosus,(41) sarcoidosis,(42) liver transplantation(43) and, 
historically, rheumatoid arthritis.(44) The recognition 
of the impact of oral corticosteroids in systemic lupus 
erythematosus has even catalyzed the development 
of a Systemic Lupus Erythematosus-Specific Steroid 
Questionnaire.(45) There have been no previous studies 
in AIH, to our knowledge, that have explored the spe-
cific impact of corticosteroids on QOL. The study by 
Schramm and colleagues found a correlation between 
rates of depression with prednisolone use in their AIH 
cohort.(14) However, no correlation was found between 
corticosteroid use and HADS-A or HADS-D in our 
study. A key conclusion of our study is that clinicians 
should be more aware of the potential for impaired life 
quality and health utility in patients with AIH who 
are on corticosteroids. This should be factored into 
decisions regarding the appropriateness of long-term 
corticosteroid therapy with clinicians being aware that 
steroid minimization, as opposed to discontinuation, 
may not confer benefit.
The use of CNIs (tacrolimus or cyclosporine) in 
AIH appears to be growing, although the evidence base 
TABLE 4. Regression Analysis Investigating the Relationship Between Corticosteroid Use and Further HRQOL Outcome 
Measures
Outcome variable Predictor Coefficient (β) 95% CI P Value
EQ-5D-5L health states: Corticosteroid usea
Mobility 0.307 (0.037, 0.578) 0.026
Self-care 0.373 (-0.054, 0.800) 0.087
Usual activities 0.426 (0.162, 0.690) 0.002
Pain/discomfort 0.203 (-0.040, 0.447) 0.102
Anxiety/depression 0.267 (0.009, 0.525) 0.043
Total FIS score 9.50 (4.12, 14.9) <0.001
CFQ score 2.46 (-0.562, 5.48) 0.111
HADS-Anxiety score 0.162 (-0.118, 0.443) 0.256
HADS-Depression score 0.327 (-0.059, 0.713) 0.096
aControlling for age, sex, and remission status.
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is limited (case-series in refractory patients). CNIs are 
well-known to have associated adverse effects such 
as renal impairment, neurotoxicity, hypertension, and 
gum hypertrophy.(4,46,47) CNIs are often second- or 
third-line therapies for azathioprine or mycophenolate 
mofetil intolerant patients or those who have failed to 
respond to conventional therapies. Although only 4% 
of our population were on CNIs, it is striking to note 
that this still emerged as a covariate significantly asso-
ciated with lower UI even after controlling for cortico-
steroid use. This highlights the need for therapies that 
are better tolerated with better efficacy.
In exploring the potential factors which might 
underpin poor quality of life and health utility in AIH, 
we found that the overall median fatigue impact scale 
(FIS) score for our AIH cohort was 27 (maximum pos-
sible score of 160). Although direct comparisons can-
not be made, this score is not dissimilar to the median 
FIS score seen in community controls(28) and AIH 
controls (21 in a cohort of 38 patients) in a previous 
study exploring the impact of fatigue in PBC (median 
FIS 40).(48) Fatigue scores were higher in patients not 
in remission and in patients taking corticosteroids, 
although fatigue did not appear to be the major driving 
force between corticosteroid-associated impairment 
of health utility. The median score for the CFQ tool 
was 32 (0-100) with a mean of 34 (SD 18). For com-
parison, a study evaluating QOL in a cohort of 103 
patients with liver transplantation (median time since 
transplantation of 40 months [range 2-155]) reported 
a mean CFQ score of 38 (SD 25.2).(49) There was no 
association between corticosteroid use and worse CFQ 
scores in our study. These observations suggest that 
in AIH, unlike in PBC, cognitive impairment symp-
toms and fatigue do not appear to be major factors in 
impaired health utility.
Our study has limitations. Firstly, it is cross-sectional 
in nature, therefore any associations found between 
HRQOL and other factors must be interpreted cau-
tiously, especially with respect to causality. Ideally, we 
would have longitudinal data on the patients in our 
cohort, which would allow the effect of treatment 
to be studied over time. In addition, the population 
norms used for comparison were based on data from 
the United Kingdom’s most recent survey in 1993. It 
is possible that average health has improved over time 
across the age groups, with the published population 
norms therefore likely to be conservative. In this large 
cohort, we observed that the association between 
corticosteroid use and reduced UI is independent of 
remission status and other known confounders (age, 
sex, comorbidity, and so on). However, there may be 
other unknown and unmeasured confounders that 
we have been unable to adjust for. Ideally, we would 
provide an interpretation of the effect size of cortico-
steroid use on UI at a patient level; however, to our 
knowledge the minimally important clinical difference 
in UI has not previously been studied in this popula-
tion. Another limitation of the study is that our data on 
comorbidities are self-reported data by patients rather 
than data based on more accurate diagnostic criteria 
which would be highly ideal, particularly for those with 
overlap or concurrent PBC or PSC. We did not collect 
socioeconomic data, which would be desirable for more 
detailed health economic analysis.
There is increasing recognition that quality of life 
management should be a priority in managing patients 
with AIH, as it can have an impact on compliance 
to medication, as well as outcomes. Despite estab-
lished therapies, little information has been published 
on HRQOL and utilities for health states resulting 
from AIH. This current study is the start of bridg-
ing this gap and it highlights the impaired HRQOL 
in patients with AIH. In addition, it can be used to 
inform on cost-effectiveness of current treatment reg-
imens in the United Kingdom. There may also be a 
role for the development of AIH-specific HRQOL 
measures, similar to the PBC-40 (a PBC-specific 
HRQOL tool).(50)
In summary, our data show evidence of HRQOL 
impairment in a large cohort of AIH patients com-
pared with the general population, as well as impair-
ment similar to that seen in patients with PBC. 
Furthermore, corticosteroid use shows an association 
with decreased HRQOL which is independent of 
remission status. This highlights the need for bet-
ter, and ideally corticosteroid-free, future therapy 
approaches and emphasizes the need for future novel 
therapeutic trials in AIH.
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